ArticleNucleic acids research2026
A modified X10-23 DNAzyme that can better access large, structured RNA targets.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chemical Modification Strategies for Therapeutic Oligonucleotides: Mechanism Compatibility, Design Trade-Offs, and Translational Barriers.Molecules (Basel, Switzerland) · 2026Review
- Allosteric DNAzyme-Enabled Sensitive and Multiplex Detection of Biomarkers for Rapid Diagnosis of Urinary Tract Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The 10-23 DNAzyme in Biosensing and Diagnostics: Applications, Challenges, and Future Directions.Angewandte Chemie (International ed. in English) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The 10-23 DNA enzyme is one of the most efficient RNA-cleaving enzymes reported, possessing substrate recognition arms that can be designed to target virtually any AU diribonucleotide junction. However, 10-23 often shows reduced activity for large, structured RNA (lsRNA) substrates like messenger RNA. Increasing arm length or adding antisense DNA oligonucleotides (ASOs) can improve accessibility to lsRNA but may also reduce the efficiency of product release. Xeno nucleic acids (XNAs), such as 2'-fluoro-arabinonucleic acid (FANA), have been substituted for DNA into the arms of 10-23 to improve activity, such as in the FANA-modified X10-23, but X10-23 also shows poor accessibility for lsRNA targets. To overcome this issue, we substituted patterns of various XNAs with high RNA binding strength into the substrate recognition arms of X10-23. We found that an X10-23 enzyme with a distinct 2'F-RNA-LNA-FANA arm pattern, denoted as XdZ-2, could gain access to several lsRNA targets from SARS-CoV-2, achieving cleavage rates up to 82-fold faster than X10-23 for one system. While the ASO strategy provided higher cleavage rates for two other lsRNA systems, XdZ-2 may be a more attractive alternative in low Mg2+ environments and in terms of improving the efficiency of product release and stability in biological samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.